2016 International Congress Archives - Page 148 of 207

Natural history of saccadic abnormalities in spinocerebellar ataxia 2: Implications to designing future clinical trials

R. Rodríguez-Labrada, L. Velázquez-Pérez, G. Auburger, U. Ziemann, Y. Vazquez-Mojena, N. Canales-Ochoa (Holguín, Germany)
ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump

R. Shaltiel-Karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas, A. Rubinski, Y.S. Schiffenbauer, A. Nyska, O. Yacoby-Zeevi (Rehovot, Israel)
Neck proprioception is impaired in patients with idiopathic cervical dystonia

J. De Pauw, R. Mercelis, A. Hallemans, S. Michiels, S. Truijen, P. Cras, W. De Hertogh (Antwerp, Belgium)
Negative dystonia of the palate: Mutation in the THAP1 (DYT6) gene found in a 42 years old patient

S. Grimaldi, E. Boutin, D. Robert, A. Lagier, D. Korchia, H. Soma, J.P. Azulay (Marseille, France)
Negative emotional signals impair isometric force control in Parkinson’s disease

R.L. Blakemore, M.R. MacAskill, R. Shoorangiz, T.J. Anderson (Christchurch, New Zealand)
Neural mechanisms underlying step initiation failure in patients with Parkinson’s disease and freezing of gait

M. Gilat, M. Georgiades, J.M. Shine, K.A. Ehgoetz Martens, C.C. Walton, J.M. Hall, S.J.G. Lewis (Sydney, Australia)
Neural plasticity and freezing of gait: Stepping through the FoG

B.W. Fling, M. Mancini, P. Carlson-Kuhta, L.A. King, K. Smulders, D.S. Peterson, N. Pal, J.G. Nutt, F.B. Horak (Portland, OR, USA)
Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson’s disease: A resting state functional MRI study

M.C. Wen, S.Y.E. Ng, H.S.E. Heng, Y. Chao, L.L. Chan, E.K. Tan, L.C.S. Tan (Singapore, Singapore)
Neuro-cognitive domain related to conversion of Parkinson’s disease dementia

S.M. Cheon, S.Y. Lee, J.W. Kim (Busan, Korea)
Neuroanatomical correlates of apathy in non-demented and non-depressed Parkinson’s disease

S. Martinez-Horta, F. Sampedro, J. Pagonabarraga, R. Fernandez-Bobadilla, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)
Neurocognitive domains of impulsivity in Parkinson’s disease (PD) and the effects of dopaminergic replacement therapy (DRT)

M. Sousa, N. Canário, F. Moreira, C. Duarte, M. Castelo-Branco, C. Januário (Coimbra, Portugal)
Neurodegeneration and microgliosis are independent of α-synuclein aggregation in a mouse model of "prion-like" α-synuclein speading

P. Garcia, W. Wemheuer, S. Brioschi, A. Masuch, E. Masliah, V. Koziel, T. Pillot, E. Koncina, C. Jaeger, A. Weihofen, R. Balling, K. Biber, M. Buttini (Esch-sur-Alzette, Luxembourg)
Neurodegeneration with brain iron accumulation (NBIA): Two cases with different subtypes and a rare mutation

N. Sozer Topcular, S. Cagirici, A. Bajrami, E. Demir, H. Akçakaya, V. Yayla (Istanbul, Turkey)
Neurodegenerative disorders with atypical course and cause, diagnostic contribution of genetics and magnetic resonance imaging, two case reports

H. Streitova, M. Balaz (Brno, Czech Republic)
Neuroleptic medication is associated with a worse health status in the years prior to treatment, but have the potential for normalization

P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson, M.S. Okun (Miami, FL, USA)
Neurologic phenotipic variability in spinocerebelar ataxia hype 2 (SCA2)

T.L. Monte, C.L. Lucas, S. Amanda, R. Estela, A. Marina, M.L.S. Pereira, J.L. Pedroso, O. Barsotini, F.R. Vargas, P. Fernanda, R. Castilho, L.B. Jardim (Porto Alegre, Brazil)
Neuromelanin imaging is useful for monitoring disease progression in Parkinson’s disease and PARK2

T. Hatano, A. Okuzumi, K. Kamagata, K. Daida, D. Taniguchi, M. Hori, H. Yoshino, S. Aoki, N. Hattori (Tokyo, Japan)
Neuromelanin in Parkinson’s disease: A 3 T MRI study

S. Pietracupa, A. Martin-Bastida, N.L. Kaim, S. Schwarz, D. Auer, A. Berardelli, P. Piccini (Rome, Italy)
Neuromelanin-MRI of substantia nigra subregions in Parkinson’s disease

L. Borellini, G. Franco, P. Trujillo, P. Summers, A. Di Fonzo, D.O. Claassen, A. Costa (Milan, Italy)
Neuron specific protein S100B and cognitive impairment in various forms parkinsonism

R.J. Matmurodov, K.M. Khalimova, N.S. Rashidova, U. Ergashev, O. Turgunhojayev (Tashkent, Uzbekistan)
Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

K. Schmeisser, A. Parker (Montreal, QC, Canada)
Neurophysiological assessment of corticospinal tract activation due to subthalamic deep brain stimulation in patients with Parkinson’s disease

P. Mahlknecht, H. Akram, D. Georgiev, J. Candelario, A. Zacharia, Z. Kefalopoulou, L. Zrinzo, J. Hyam, M. Hariz, C. Milabo, T. Foltynie, J.C. Rothwell, P. Limousin (Innsbruck, Austria)
Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing

S. Martinez-Horta, J. Perez-Perez, A. Horta-Barba, R. Fernandez-Bobadilla, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)
Neurophysiological investigation of brainstem in idiopathic REM sleep behavior disorder (iRBD) through vestibular evoked myogenic potentials (VEMPs)

E.R. de Natale, F. Ginatempo, I. Laccu, B. Mercante, A. Manca, M. Figorilli, M. Puligheddu, F. Deriu (Sassari, Italy)
Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study

A. Wasik, I. Romanska, L. Antkiewicz-Michaluk (Krakow, Poland)
Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat

L.R. Antkiewicz-Michaluk (Krakow, Poland)
Neuroprotective potential of L-theanine against excitotoxic neuronal death induced by quinolinic acid: Possible neurotransmitters and nitric oxide modulation mechanism

S. Jamwal, P. Kumar (Moga, India)
Neuropsychiatric disturbances in Parkinson’s disease patients’ with chronic pain

G. Pavlic, I. Moldovanu, N. Diaconu, L. Rotaru (Chisinau, Republic of Moldova)
Neuropsychiatric, personality and non-motor correlates of impulse control disorders in recent onset Parkinson’s disease

D.M.A. Swallow, M.A. Lawton, K.A. Grosset, N. Malek, N. Bajaj, R.A. Barker, Y. Ben-Shlomo, D.J. Burn, T. Foltynie, J. Hardy, H.R. Morris, N. Williams, N.W. Wood, D.G. Grosset, PRoBaND Collaborators (Glasgow, United Kingdom)
Neuropsychological assessment in a cohort of patients with Parkinson’s disease

C. Juri, W. Uslar, H. Farias, M. Vasquez (Santiago, Chile)
Neuropsychological assessment in the Luxembourg Parkinson’s cohort (HELP-PD)

G. Hipp, P. Kolber, K. Roomp, M. Kerschenmeyer, S.K. Mosch, L. Longhino, A. Schweicher, M. Faltz, V.P. Satagopam, N. Goncharenko, M. Gantenbein, M. Vaillant, F. Betsou, A. Chioti, R. Schneider, R. Schneider, R. Balling, N.J. Diederich, R. Krüger (Belvaux, Luxembourg)
Neuropsychological correlates of impulse control disorders and punding in Parkinson´ s disease

G. Santangelo, F. Falco, M. Vicidomini, R. Allocca, P. Barone, C. Vitale (Caserta, Italy)
Neuropsychological safety of bilateral pallidal (GPi) deep brain stimulation (DBS) for Parkinson’s disease (PD) under general anesthesia

A.I. Tröster, F.A. Ponce, L. Autry, M. Lambert, V.G. Evidente, S. Oravivattanakul, A. Lieberman, G. Moguel-Cobos, N. Salins, K. Hanson (Phoenix, AZ, USA)
Neuropsychological subgroups in non-demented Parkinson’s disease: A latent class analysis

L. Brennan, K. Devlin, S.X. Xie, D. Mechanic-Hamilton, B. Tran, H. Hurtig, A. Chen-Plotkin, L. Chahine, J.F. Morley, J.E. Duda, D.R. Roalf, N. Dahodwala, J. Rick, J.Q. Trojanowski, P.J. Moberg, D. Weintraub (Philadelphia, PA, USA)
Neuropsychology and magnetic resonance correlation in Parkinson´s disease mild cognitive impairment: Case-control study

L.F.R. Vasconcellos, M. Adachi, D. Greca, M. Cruz, A.L. Malak, H. Charchat-Fichman, J.S. Pereira (Rio de Janeiro, Brazil)
New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)
Next-generation profiling to identify the molecular etiology of Parkinson’s disease dementia

E.D. Driver-Dunckley, J. Corneveaux, D.B. Matt, L. Cuyugan, W. Liang, M. Huentelman, T.G. Beach, C.H. Adler, A. Henderson-Smith, T. Dunckley (Scottsdale, AZ, USA)
Nighttime sleep problems in patients with Parkinson’s disease: Risk factors and longitudinal associations

K. Zhu, J.J. van Hilten, J. Marinus (Leiden, Netherlands)
Nigrostriatal degeneration and serum BDNF levels in patients with “de novo” untreated Parkinson’s disease

G. Marti, N. Saez, M. Corominas, G. Cuberas, C. Lorenzo, O. De Fabregues, J. Alvarez-Sabin, M. Casas, J. Hernandez (Barcelona, Spain)
Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)
Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)
Ninjurin 1 gene D110a single nucleotide polymorphism as a genetic marker for nerve damage leprosy patients from South India

A. Sundaramoorthy, S. Keshavarao, A. Valsala Gopalakrishnan (Coimbatore, India)
No RAB39B gene mutations in Chinese familial Parkinson’s disease

J.F. Guo, J.F. Kang, X.X. Yan, B.S. Tang (Changsha, People's Republic of China)
Non motor symptoms burden and motor staging of Parkinson’s disease: Evidence for dichotomy and non-motor dominant subtypes from analysis of 249 cases

K. Ray Chaudhuri, A. Sauerbier, T. Thavayogarajah, A. Rizos, L. Perkins, C. Rodriguez Blazquez, P. Martinez-Martin, On behalf of EUROPAR, the MDS Non-Motor PD Study Group, The NILS Group (London, United Kingdom)
Non motor symptoms of Parkinson’s disease: Prevalence and impact on quality of life

M. Chraa, K. Choulli, N. Kissani (Marrakech, Morocco)
Non-contact boxing in Parkinson’s disease

Z.R. Yee, S.H.X. Liew (Singapore, Singapore)
Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on the location of active contacts

H.S. Dafsari, J.N. Petry-Schmelzer, K. Ashkan, L. Weis, T. Dembek, M. Samuel, A. Rizos, M. Silverdale, J. Evans, P. Martinez-Martin, A. Antonini, K.R. Chaudhuri, V. Visser-Vandewalle, L. Timmermann (Cologne, Germany)
Non-motor symptoms (NMS) as a determinant of caregiver burden in a cohort of older patients with Parkinson’s disease (PD)

S. Gangadharan, N. Bareham, A. Johnson, M. Rees, A. Withenage, C.P. Padmakumar (Newcastle, Australia)
Non-motor symptoms evaluation in idiopathic cervical dystonia

N. Novaretti, V. Tumas (Ribeirão Preto, Brazil)
Non-motor symptoms in a PPMI cohort of p.A53T α-synuclein mutation-related and sporadic Parkinson’s disease patients

C. Koros, M. Stamelou, I. Beratis, N. Papagiannakis, A.M. Simitsi, D. Papadimitriou, S. Fragiadaki, D. Kontaxopoulou, S.G. Papageorgiou, L. Stefanis (Athens, Greece)
Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis

K.R. Chaudhuri, E. Terasawa, Y. Jalundhwala, D. Macaulay, R. Ayyagari, Z.Y. Zhou, T. Marshall, K. Chatamra, A. Yucel, K. Sail (London, United Kingdom)
Non-motor symptoms in PD candidates for DBS treatment

M.G. dos Santos Ghilardi, R.C.R. Martinez, R.G. Cury, J.R. Aranha, M.J. Teixeira, E.R. Barbosa, E.T. Fonoff (Sao Paulo, Brazil)
Non-motor symptoms in progressive supranuclear palsy

R. Ou, W. Song, Q. Wei, K. Chen, B. Cao, Y. Hou, B. Zhao, H. Shang (Chengdu, People's Republic of China)
Non-motor symptoms profiles in UK white Caucasian and Asian as well as overseas Thai and East Indian patients with Parkinson’s disease

A. Sauerbier, O. Jitkritsadakul, R. Bhidayasiri, H. Kumar, P. Martinez-Martin, R. Banerjee, M. Kulsum, A. Rizos, G. Harington, L. Perkins, T. Chiwera, D. Trivedi, A. Martin, M. Parry, R. Brown, J. Al-Hashel, W. Kamel, A. Kilany, S. Lim, A. Tan, K. Bhattacharyya, R. Walker, K. Ray Chaudhuri, On behalf of EUROPAR, the MDS Non-Motor PD Study Group and the NILS Group (London, United Kingdom)
Non-motor symptoms trajectory in Parkinson’s disease: Magnitude and importance of the change

C. Rodriguez-Blazquez, A. Rizos, K.R. Chaudhuri, P. Martinez-Martin, NILS, EUROPAR and the MDS Non Motor PD Study Groups (Madrid, Spain)
Novel PLA2G6 c.1627C>T homozygous mutation and response to DBS-GPi

A.D. Magalhães, L. Correia Guedes, M. Coelho, T. Teodoro, A. Valadas, H. Carvalho, B. Cattoni, J.J. Ferreira (Lisbon, Portugal)
Novel mutations identified in dopamine transporter deficiency syndrome

J. Ng, J. Zhen, K. Erreger, N.C. Oien, S. Mohammed, J.P. Linn, J. Muntadas, I. Denzler, A. Garcia Cazorla, R. Artuch, S. Pope, S.J.R. Heales, A. Galli, M.E.A. Reith, M.A. Kurian (London, United Kingdom)
Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease

E. Tsika, A. Davranche, J. Molette, E. Gabellieri, S. Papin, S. Nampally, H. Kroth, D. Lowe, A. Pfeifer, A. Muhs (Lausanne, Switzerland)
Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)
Novel THAP1 missense mutation leading to focal and segmental dystonia

D. Crosiers, C. Van Broeckhoven, P. Cras (Edegem, Belgium)
Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)
Novel variants in the SACS gene in a first Central-Eastern European family with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)

M. Schinwelski, M. Krygier, J. Slawek, M. Zuk, M. Rydzanicz, A. Walczak, P. Stawinski, A. Konkel, M. Sildatke-Bauer, R. Ploski, J. Limon (Gdansk, Poland)
NREM parasomnias as a marker of cognitive impairment in Parkinson’s disease

B. Minafra, M. Terzaghi, R. Zangaglia, N.G. Pozzi, M. Picascia, R. Cremascoli, E. Sinforiani, N. Vanacore, R. Manni, C. Pacchetti (Pavia, Italy)
Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy

M.H.S. Tosin, B.G.R.B. Oliveira, T.R. Garcia (Rio de Janeiro, Brazil)
Nutritional status and quality of life in patients with Parkinson’s disease in a tertiary hospital in Northeast Mexico

I.E. Estrada, P. Ancer, H.J. Villarreal, C. Lopez, J. Rocha, A. Treviño, J.J. Peña, D. Ortiz (Monterrey, Mexico)
Nystagmus in essential tremor

N. Biary, M. Al Zawahmah, W. Khoja, A. Al Abdulsalam (Riyadh, Saudi Arabia)
Nystagmus in harmaline induced tremors in rats and attenuation with ethanol

N. Biary, A. Al Asmari, M. Arshaduddin, M. Al Zawahmah (Riyadh, Saudi Arabia)